Kiniksa Pharmaceuticals International, plc Stock Price, News & Analysis

Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported Q3 2025 results and portfolio updates on October 28, 2025. ARCALYST net product revenue was $180.9M in Q3, a 61% year-over-year increase, leading Kiniksa to raise 2025 ARCALYST guidance to $670M–$675M (from $625M–$640M). The company reported net income of $18.4M in Q3 versus a net loss of $12.7M in Q3 2024. Cash, cash equivalents and short-term investments rose by $44.3M to $352.1M as of September 30, 2025, with no debt.

Pipeline news: FDA granted Orphan Drug Designation to KPL-387 for pericarditis; Phase 2 dose-finding data expected in H2 2026, then pivotal start. KPL-1161 remains in IND-enabling work.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report third quarter 2025 results and recent portfolio execution on Tuesday, October 28, 2025 at 8:30 a.m. ET. The company will host a conference call and live webcast accessible via the Investors & Media section of www.kiniksa.com.

Participants can register to join by telephone and will receive a confirmation email with dial-in details, a unique passcode, and registrant ID. A replay will be available on Kiniksa’s website approximately 48 hours after the event.

Kiniksa (Nasdaq: KNSA) announced that the U.S. FDA granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, including recurrent pericarditis, on October 17, 2025.

KPL-387 is an independently developed monoclonal antibody that binds IL-1R1, inhibiting signaling of IL-1α and IL-1β. The company highlights potential dosing as a single monthly subcutaneous self-injection in a liquid formulation. Data from the Phase 2 dose-focusing portion of the Phase 2/3 recurrent pericarditis trial are expected in the second half of 2026.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in two major investor conferences in September 2025. The company's management will engage in fireside chats at the Citi 2025 Biopharma Back to School Summit on September 3 at 9:00 a.m. ET and the 2025 Wells Fargo Healthcare Conference on September 4 at 9:30 a.m. ET.

Both presentations will be available via live webcast through Kiniksa's website investor section, with replays accessible within 48 hours after each event.

Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported strong Q2 2025 financial results, with ARCALYST net product revenue reaching $156.8 million, representing a 52% year-over-year growth. The company raised its 2025 ARCALYST revenue guidance to $625-640 million from $590-605 million.

Key highlights include net income of $17.8 million compared to a $3.9 million loss in Q2 2024, and a robust cash position of $307.8 million. ARCALYST's commercial success continues with over 3,475 prescribers and approximately 15% penetration of the target 14,000 multiple-recurrence patient population.

The company also announced progress in its pipeline, initiating the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, with Phase 2 data expected in 2H 2026.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) has scheduled its second quarter 2025 financial results conference call and webcast for Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time. The company will discuss its Q2 2025 financial performance and recent portfolio developments.

Investors can access the live webcast through the Investors & Media section on www.kiniksa.com. For telephone participation, interested parties must pre-register to receive dial-in details. A replay will be available on the company's website within 48 hours after the event.

Kiniksa Pharmaceuticals announced details of its planned Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, set to begin mid-2025. KPL-387 is a monoclonal antibody targeting IL-1R1 to inhibit IL-1α and IL-1β signaling. The trial will include three parts: a dose-focusing Phase 2 with 80 participants testing different dosing regimens, a pivotal Phase 3 portion with 85 patients, and long-term extensions. The Phase 2 portion will evaluate four different dosing schedules, with data expected in 2H 2026. The Phase 3 segment will include a single-blind run-in period followed by a randomized withdrawal period. The drug's development leverages Kiniksa's experience with the RHAPSODY study design and aims to provide monthly dosing via single subcutaneous injection in a liquid formulation.

Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its participation in two major investor conferences in June 2025. The company will present at the Jefferies 2025 Global Healthcare Conference on June 5 at 12:50 p.m. ET and participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 8:00 a.m. ET. Both presentations will be available via live webcast through Kiniksa's website in the Investors & Media section, with replays accessible within 48 hours after each event.

[]

Kiniksa Pharmaceuticals has partnered with GRAMMY Award-winning country star Carly Pearce for their Life DisRPted™ campaign, focusing on raising awareness for recurrent pericarditis. Pearce, who was diagnosed with the condition in 2024 after experiencing multiple flares over four years, joins NHL Hall-of-Famer Henrik Lundqvist in the campaign.

The initiative aims to educate patients and caregivers about this chronic autoinflammatory heart disease, which is often underdiagnosed. Through a video titled "The Power of Knowing" available on LifeDisRPted.com, Pearce shares her personal journey and emphasizes the importance of self-advocacy.

Recurrent pericarditis symptoms include:

• Chest pain
• Tiredness
• Shortness of breath
• Reduced exercise capacity

The campaign provides resources including a Doctor Discussion Guide to help patients better communicate with healthcare providers.